Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVANNAH: Osimertinib + Savolitinib in EGFRm+ MET+ NSCLC
NCT03778229Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised trial of savolitinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate up to 5.6 years. Started Jan 2019; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03778229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778229.